Chemocentryx, inc. (CCXI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Revenue:
Collaboration and license revenue from related party

5,855

9,871

10,581

7,173

8,327

9,332

8,975

15,022

9,546

-

-

-

8,230

-

4,251

2,795

-

-

-

-

0

-

-

-

0

725

1,522

1,886

1,927

2,145

1,128

1,128

1,018

26,052

1,441

1,232

2,948

Grant revenue

153

-

-

-

-

-

-

-

-

-

-

-

-

-

120

175

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenue

6,008

10,047

10,581

7,173

8,327

9,332

8,975

15,022

9,546

56,301

9,029

8,937

8,230

-

4,131

2,620

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

19,311

19,202

18,096

17,624

15,354

15,100

15,135

17,759

14,742

12,881

12,315

14,329

9,970

9,249

8,389

9,062

11,245

8,230

7,931

8,602

8,420

9,121

7,543

9,002

8,149

7,417

8,193

8,676

9,255

9,220

8,746

9,694

6,909

5,445

8,321

7,273

7,320

General and administrative

8,820

6,968

6,116

5,570

5,501

5,628

5,373

4,748

4,660

4,128

3,624

4,184

4,573

3,556

3,193

3,877

4,084

3,430

3,811

3,576

3,689

3,169

3,510

3,382

3,523

2,979

2,882

2,809

2,964

2,826

2,619

2,473

2,562

1,894

1,772

1,941

2,008

Total operating expenses

28,131

26,170

24,212

23,194

20,855

20,728

20,508

22,507

19,402

17,009

15,939

18,513

14,543

12,805

11,582

12,939

15,329

11,660

11,742

12,178

12,109

12,290

11,053

12,384

11,672

10,396

11,075

11,485

12,219

12,046

11,365

12,167

9,471

7,339

10,093

9,214

9,328

Loss from operations

-22,123

-16,123

-13,631

-16,021

-12,528

-11,396

-11,533

-7,485

-9,856

39,292

-6,910

-9,576

-6,313

-7,916

-7,331

-10,144

-15,329

-11,660

-11,742

-12,178

-12,109

-12,290

-11,053

-12,384

-11,672

-9,671

-9,553

-9,599

-10,292

-9,901

-10,237

-11,039

-8,453

18,713

-8,652

-7,982

-6,380

Other income (expense):
Interest income

984

1,113

1,311

1,418

1,121

1,057

1,066

792

613

367

350

336

317

251

259

161

86

86

95

100

103

103

116

129

146

141

134

110

116

122

141

167

103

83

95

105

119

Interest expense

548

518

542

547

542

446

423

181

174

-

-

-

-

-

-

-

-

-

-

-

-

3

4

6

11

13

14

15

17

18

20

21

735

564

117

26

27

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16

-

-

Total other income, net

436

595

769

871

579

611

643

611

439

363

350

336

317

251

259

161

86

86

95

100

103

100

112

123

135

128

120

95

99

104

121

146

-632

-481

-6

79

92

Net loss

-21,687

-15,528

-12,862

-15,150

-11,949

-10,785

-10,890

-6,874

-9,417

39,655

-6,560

-9,240

-5,996

-7,665

-7,072

-9,983

-15,243

-11,574

-11,647

-12,078

-12,006

-12,190

-10,941

-12,261

-11,537

-9,543

-9,433

-9,504

-10,193

-9,797

-10,116

-10,893

-9,085

18,232

-8,658

-7,903

-6,288

Shares used to compute net (loss) income per common share
Basic and diluted net loss per common share

-0.35

-

-0.22

-0.26

-0.23

-

-0.22

-0.14

-0.19

-

-0.13

-0.19

-0.12

-

-0.15

-0.22

-0.34

-

-0.26

-0.28

-0.28

-0.28

-0.25

-0.28

-0.27

-0.22

-0.22

-0.23

-0.28

-0.27

-0.28

-0.30

-0.28

4.38

-2.06

-1.90

-1.52

Shares used to compute basic and diluted net loss per common share

61

-

58

58

52

-

50

49

48

-

48,602

48,224

48,115

-

47

45

44

-

44

43

43

-129,543

43,336

43,274

43,107

-120,623

42,839

41,337

36,611

36,348

36,180

36,169

32,931

-12,470

4,201

4,151

4,135